The statistical analysis presented a notable reduction in the relative amounts of β-catenin and its target gene MYC in HCC tumors after treatment with Sorafenib (β-catenin (p-value= 0.02724), MYC (p-value= 0.04531)) or NK cells ((β-catenin (p-value= 0.07618), MYC (p-value= 0.00219)) compared to control group in Fig. 5. Here, MYC is linked to hepatocellular carcinoma.